Both in Pharmaceuticals
NextCure vs Celularity
Over the past year NXTC returned −38.7% and CELU returned −53.0%; their daily moves had a correlation of 0.08.
NXTC −38.7% CELU −53.0%Growth of $1, one year, split-adjusted
| Metric | NXTC | CELU |
|---|---|---|
| Price | $6.34 | $0.9401 |
| Market cap | $29.0M | $30.5M |
| Today | +10.94% | +18.97% |
| 1 month | +30.9% | −31.4% |
| 6 months | −29.1% | −2.1% |
| Year to date | −55.3% | −15.3% |
| 1 year | −31.6% | −55.0% |
| Revenue growth (YoY) | — | −5.3% |
| Gross margin | — | 56.8% |
| Net margin | — | 10.1% |
| P/E (TTM) | — | — |
| Price / sales | — | 1.6× |
| Net cash | $20.1M | -$37.1M |
| Dividend yield | — | — |
| Volatility (60d) | 115.9% | 222.5% |
| Short % of float | 8.4% | 6.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).